Bryan Brokmeier


Cantor Remains Confident on Pacific Biosciences of California (PACB) While Shares Crash 42%

Pacific Biosciences of California (NASDAQ:PACB) shares are on a 42% nosedive after announcing this morning before market open that Roche has terminated its collaboration …

Cantor Weighs In on Cerus Corporation (CERS) as FDA Halted Blood Donations in Two FL Counties Due to Zika

Cantor analyst Bryan Brokmeier reiterated a Buy rating on shares of Cerus Corporation (NASDAQ:CERS), with a $9.00 price target, after the FDA announced that it is requesting that …

Cantor Neutral with a Side of Caution on Illumina, Inc. (ILMN) Following 2Q:16 Results

Following market close yesterday, Illumina, Inc. (NASDAQ:ILMN) reported second quarter revenue results of $600.

Cantor Assumes Buy on Cerus Corporation (CERS), Sees 40% Upside for the Stock

In a research report sent to investors Thursday, Cantor analyst Bryan Brokmeier assumed coverage on shares of Cerus Corporation (NASDAQ:CERS), with a Buy rating and price …

Cantor Initiates Buy on TrovaGene Inc; Sees 56% Upside for the Stock

In a research report published yesterday, Cantor analyst Bryan Brokmeier initiated coverage on shares of TrovaGene Inc (NASDAQ:TROV) with a Buy rating and price …

Cantor Initiates Buy on Illumina, Inc.; Sees 32% Upside for the Stock

In a research report released yesterday, Cantor analyst Bryan Brokmeier initiated coverage on shares of Illumina, Inc. (NASDAQ:ILMN) with a Buy rating and a …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts